Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Medicine, Molecular Biology, Oncology +14

Fusion of a Kinase Gene, <i>ALK</i> , to a Nucleolar Protein Gene, <i>NPM</i> , in Non-Hodgkin's Lymphoma

Stephan W. Morris, Mark N. Kirstein, Marcus B. Valentine et al. · Science · 1994 · 2.4K citations

Medicine, Genetics, Oncology +17

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, Peter Hirth, James Tsai et al. · Nature · 2010 · 1.8K citations

Medicine, Oncology, Pharmacology +14

Identification of ALK as a major familial neuroblastoma predisposition gene

Yaël P. Mossé, Marci Laudenslager, Luca Longo et al. · Nature · 2008 · 1.4K citations

Life Sciences, Genetics, Molecular Genetics +10

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations

Medicine, Oncology, Pharmacology +15